Inhalation Sciences receives service order from recurring global pharmaceutical customer

Stockholm, July 1, 2025 - Inhalation Sciences Sweden AB (ISAB) today announces that the company has received a new service order from a recurring global pharmaceutical customer worth EUR 14,250 (158,600 SEK). The customer has previously invested in several of ISAB's advanced research instruments and has now expanded its collaboration by signing an additional service agreement and more service agreements are underway.

The new agreement covers continued service and technical support for the customer's existing installations of ISAB's patented research platform PreciseInhale®, which is used in preclinical inhalation research with high reproducibility and precision. The customer, a leading player in inhaled pharmaceuticals, has its headquarters in Europe.

"The fact that a global pharmaceutical player with several of our instruments chooses to further deepen the collaboration through a new service agreement is a strong confirmation of the long-term value and reliability of our technologies. Our ability to provide high-quality technical support is an important part of our customer promise, and we look forward to continuing to strengthen these relationships", says Manoush Masarrat, CEO of Inhalation Sciences.

The order is in line with ISAB's strategy to build recurring revenue streams and support its partners throughout the inhalation research lifecycle.

For more information, please contact:

Manoush Masarrat, CEO
Mobile: +46 (0)73 628 9153 
E-mail: manoush.masarrat@inhalation.se